551.25
price up icon1.24%   6.74
after-market アフターアワーズ: 553.10 1.85 +0.34%
loading
前日終値:
$544.51
開ける:
$555
24時間の取引高:
276.53K
Relative Volume:
0.86
時価総額:
$12.71B
収益:
$1.13B
当期純損益:
$-309.44M
株価収益率:
-43.07
EPS:
-12.8001
ネットキャッシュフロー:
$-275.41M
1週間 パフォーマンス:
+2.90%
1か月 パフォーマンス:
+7.53%
6か月 パフォーマンス:
+10.16%
1年 パフォーマンス:
+84.74%
1日の値動き範囲:
Value
$548.68
$566.18
1週間の範囲:
Value
$526.61
$566.18
52週間の値動き範囲:
Value
$286.44
$615.00

Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile

Name
名前
Madrigal Pharmaceuticals Inc
Name
セクター
Healthcare (1074)
Name
電話
404-380-9263
Name
住所
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Name
職員
915
Name
Twitter
@MadrigalPharma
Name
次回の収益日
2026-07-30
Name
最新のSEC提出書
Name
MDGL's Discussions on Twitter

Compare MDGL vs VRTX, REGN, ARGX, RVMD, ALNY

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
MDGL icon
MDGL
Madrigal Pharmaceuticals Inc
551.25 12.55B 1.13B -309.44M -275.41M -12.80
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
479.00 121.16B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
667.17 68.78B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
888.82 57.44B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
188.07 40.23B 742.00K -1.37B -1.07B -7.0731
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
278.40 36.28B 4.29B 577.22M 641.34M 4.2086

Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-01-28 開始されました Barclays Overweight
2026-01-06 ダウングレード Wolfe Research Outperform → Peer Perform
2025-11-05 アップグレード Cantor Fitzgerald Neutral → Overweight
2025-11-03 アップグレード BofA Securities Underperform → Neutral
2025-10-15 開始されました Truist Buy
2025-09-04 再開されました H.C. Wainwright Buy
2025-02-28 アップグレード B. Riley Securities Neutral → Buy
2025-02-27 繰り返されました H.C. Wainwright Buy
2024-06-28 開始されました Cantor Fitzgerald Neutral
2024-06-11 開始されました Wolfe Research Outperform
2024-04-22 開始されました BofA Securities Underperform
2024-03-15 アップグレード B. Riley Securities Sell → Neutral
2024-03-06 開始されました Citigroup Buy
2024-02-26 ダウングレード B. Riley Securities Neutral → Sell
2022-12-20 繰り返されました Oppenheimer Outperform
2022-12-19 繰り返されました H.C. Wainwright Buy
2022-12-19 繰り返されました Piper Sandler Overweight
2022-12-19 アップグレード Raymond James Underperform → Mkt Perform
2022-07-08 ダウングレード B. Riley Securities Buy → Neutral
2021-10-07 開始されました Jefferies Buy
2021-08-06 アップグレード BMO Capital Markets Market Perform → Outperform
2021-05-20 再開されました Goldman Buy
2020-11-24 再開されました Evercore ISI Outperform
2020-11-06 繰り返されました H.C. Wainwright Buy
2020-07-31 開始されました Piper Sandler Overweight
2020-06-05 開始されました BMO Capital Markets Market Perform
2020-05-05 開始されました Chardan Capital Markets Buy
2020-01-30 開始されました Canaccord Genuity Buy
2020-01-09 アップグレード UBS Neutral → Buy
2019-11-07 繰り返されました H.C. Wainwright Buy
2019-06-25 開始されました Stifel Hold
2019-06-10 アップグレード B. Riley FBR Neutral → Buy
2019-02-28 繰り返されました H.C. Wainwright Buy
2019-02-22 開始されました SVB Leerink Outperform
2019-01-23 開始されました UBS Neutral
2018-12-14 開始されました Wolfe Research Outperform
2018-12-12 開始されました B. Riley FBR Neutral
2018-11-19 ダウングレード Raymond James Mkt Perform → Underperform
2018-11-16 アップグレード Evercore ISI In-line → Outperform
2018-09-04 開始されました Citigroup Buy
2018-08-06 ダウングレード Goldman Buy → Neutral
2018-06-28 開始されました Raymond James Mkt Perform
すべてを表示

Madrigal Pharmaceuticals Inc (MDGL) 最新ニュース

pulisher
10:53 AM

Madrigal Pharmaceuticals Inc (MDGL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

10:53 AM
pulisher
10:11 AM

MDGL Initiated Coverage by Wells Fargo -- Rating Set to Overweig - GuruFocus

10:11 AM
pulisher
Jul 25, 2026

Madrigal Pharmaceuticals, Inc. Revenue Breakdown – XETR:YDO1 - TradingView

Jul 25, 2026
pulisher
Jul 24, 2026

Madrigal Pharmaceuticals Inc (MDGL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Jul 24, 2026
pulisher
Jul 22, 2026

BofA Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Hold Rating, Raises Target Price to $553 - Moomoo

Jul 22, 2026
pulisher
Jul 22, 2026

Madrigal Pharmaceuticals CEO Sibold sells $1.37 million in shares By Investing.com - Investing.com Australia

Jul 22, 2026
pulisher
Jul 21, 2026

UBS Initiates Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Announces Target Price $669 - Moomoo

Jul 21, 2026
pulisher
Jul 21, 2026

Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4) - TradingView

Jul 21, 2026
pulisher
Jul 21, 2026

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jul 21, 2026
pulisher
Jul 21, 2026

Madrigal New Hires Receive Options With $550.25 Exercise Price - Stock Titan

Jul 21, 2026
pulisher
Jul 21, 2026

Form 4 Madrigal Pharmaceuticals Inc For: 21 July By Investing.com - Investing.com South Africa

Jul 21, 2026
pulisher
Jul 21, 2026

Form 144 Madrigal Pharmaceuticals For: 21 July By Investing.com - Investing.com Nigeria

Jul 21, 2026
pulisher
Jul 21, 2026

Madrigal Pharmaceuticals CEO Sibold sells $1.37 million in shares - Investing.com

Jul 21, 2026
pulisher
Jul 20, 2026

Madrigal Pharmaceuticals (MDGL) insider files Form 144 for 2,500-share sale - Stock Titan

Jul 20, 2026
pulisher
Jul 20, 2026

Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis: Exploring a 22.65% Potential Upside - DirectorsTalk Interviews

Jul 20, 2026
pulisher
Jul 19, 2026

Trading the Move, Not the Narrative: (MDGL) Edition - Stock Traders Daily

Jul 19, 2026
pulisher
Jul 17, 2026

Citizens JMP Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Cuts Target Price to $739 - Moomoo

Jul 17, 2026
pulisher
Jul 17, 2026

Citizens raises Madrigal Pharmaceuticals price target on lower tax assumptions - Investing.com Nigeria

Jul 17, 2026
pulisher
Jul 16, 2026

Madrigal management to discuss Q2 results at 8 a.m. Eastern July 30 - Stock Titan

Jul 16, 2026
pulisher
Jul 16, 2026

Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026 - The Manila Times

Jul 16, 2026
pulisher
Jul 16, 2026

Is Madrigal Pharmaceuticals (MDGL) Fully Valued Ahead Of Its July 30 Earnings? - Sahm

Jul 16, 2026
pulisher
Jul 16, 2026

Guojin Securities: The MASH sector is seeing intensive, multi‑dimensional catalysts come to fruition, and Madrigal is expected to maintain double-digit growth over the long term. - Moomoo

Jul 16, 2026
pulisher
Jul 15, 2026

Lobbying Update: $120,000 of MADRIGAL PHARMACEUTICALS INC. lobbying was just disclosed | MDGL Stock News - Quiver Quantitative

Jul 15, 2026
pulisher
Jul 15, 2026

Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Biogen (BIIB) and Cadrenal Therapeutics, Inc. (CVKD) - The Globe and Mail

Jul 15, 2026
pulisher
Jul 14, 2026

BofA Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Hold Rating, Maintains Target Price $542 - Moomoo

Jul 14, 2026
pulisher
Jul 13, 2026

MDGL Stock In Focus — Retail Traders Buzz Over M&A Speculation And Pipeline Moves - Yahoo Finance

Jul 13, 2026
pulisher
Jul 13, 2026

Madrigal Pharmaceuticals' Three New Patents Support Patent Extension Into 2045, Truist Says - Moomoo

Jul 13, 2026
pulisher
Jul 13, 2026

Madrigal Doubles Down On MASH With A $4.4 Billion Licensing Deal With China’s Ribo - Stocktwits

Jul 13, 2026
pulisher
Jul 13, 2026

Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio - BioBuzz

Jul 13, 2026
pulisher
Jul 13, 2026

Madrigal receives three new U.S. patents for resmetirom drug - Investing.com

Jul 13, 2026
pulisher
Jul 13, 2026

Madrigal receives three new U.S. patents for resmetirom drug By Investing.com - Investing.com South Africa

Jul 13, 2026
pulisher
Jul 13, 2026

Madrigal Pharmaceuticals (MDGL) Secures New Patents to Enhance I - GuruFocus

Jul 13, 2026
pulisher
Jul 13, 2026

New Rezdiffra patents extend Madrigal’s MASH IP into cirrhosis care - Stock Titan

Jul 13, 2026
pulisher
Jul 13, 2026

Madrigal Grants Equity Awards to Seven New Employees - MyChesCo

Jul 13, 2026
pulisher
Jul 13, 2026

Barclays Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $964 - Moomoo

Jul 13, 2026
pulisher
Jul 13, 2026

Madrigal Pharmaceuticals, Inc. (MDGL) Investor Outlook: Unpacking a 26.46% Potential Upside - DirectorsTalk Interviews

Jul 13, 2026
pulisher
Jul 10, 2026

Madrigal Pharmaceuticals Slides 4.2% as Clear Negative Catalyst Remains Hard to Pin Down - Quiver Quantitative

Jul 10, 2026
pulisher
Jul 10, 2026

3 Under-the-Radar Stocks to Buy and Hold - Yahoo Finance

Jul 10, 2026
pulisher
Jul 08, 2026

BofA lowers its Price Target on Madrigal Pharmaceuticals, Inc. (MDGL) - Insider Monkey

Jul 08, 2026
pulisher
Jul 07, 2026

5 Best Under-the-Radar Stocks to Invest In - Insider Monkey

Jul 07, 2026
pulisher
Jul 06, 2026

Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis: Navigating a Promising 28.52% Upside Potential - DirectorsTalk Interviews

Jul 06, 2026
pulisher
Jul 06, 2026

Madrigal gives seven new employees stock awards to join the company - Stock Titan

Jul 06, 2026
pulisher
Jul 02, 2026

MDGLMadrigal Pharmaceuticals Inc Latest SEC Filings - Finviz

Jul 02, 2026
pulisher
Jul 02, 2026

Ribocure and Madrigal nominate siRNA drug candidate for MASH - BioWorld News

Jul 02, 2026
pulisher
Jul 02, 2026

Enterprise value to EBITDA forward of Madrigal Pharmaceuticals, Inc. – NASDAQ:MDGL - TradingView

Jul 02, 2026
pulisher
Jul 01, 2026

Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH - Lelezard

Jul 01, 2026
pulisher
Jul 01, 2026

Madrigal and Ribo start IND-enabling studies after MASH milestone - Stock Titan

Jul 01, 2026
pulisher
Jun 29, 2026

Enterprise value to revenue forward of Madrigal Pharmaceuticals, Inc. – NASDAQ:MDGL - TradingView

Jun 29, 2026
pulisher
Jun 29, 2026

Piper Sandler reiterates Madrigal Pharmaceuticals stock rating - Investing.com

Jun 29, 2026
pulisher
Jun 29, 2026

Piper Sandler reiterates Madrigal Pharmaceuticals stock rating By Investing.com - Investing.com Canada

Jun 29, 2026
pulisher
Jun 29, 2026

Piper Sandler Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $900 - Moomoo

Jun 29, 2026

Madrigal Pharmaceuticals Inc (MDGL) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$91.09
price up icon 1.97%
$118.87
price up icon 1.02%
$34.72
price down icon 0.83%
$58.73
price down icon 0.17%
ONC ONC
$325.90
price up icon 0.00%
$278.40
price up icon 2.44%
大文字化:     |  ボリューム (24 時間):